Go-to-Market Strategy for Leading Global Pharmaceutical Company:• Ideated to develop a market structure analyzing the $17M presbyopia market and its market value drivers, enabling client to preemptively position their category-defining FDA-approved presbyopia eye drop in the market• Facilitated cross-functional workshop with 40+ stakeholders between the client and 10 other agencies to enable the iteration of the therapeutic brand’s launch plan• Created a brand plan strategic narrative utilized by client to showcase the performance of the drug in the months after its launch and to present to C-suite executivesGrowth Strategy for Leading Global Software Company/Deloitte Internal:• Led marketing workstream aimed at shaping Deloitte’s POV on the future of customer engagement in preparation for partnership with a large software company aimed at developing a novel biopharmaceutical CRM application projected to capture an additional $230M+ in annual revenue• Conceived the development of a microsite and an executive roundtable conversation to be launched under a constrained 6-week timeline tracking toward the partnership announcement at an international software conference

Growth Strategy for Leading Global Pharmaceutical Company:• Developed behavioral/attitudinal segmentation of ~7,000 US ophthalmologists through regression analysis, allowing client to better allocate their sales resources toward high-return physician targets • Identified opportunities to achieve a ~70% ($24M) sales increase over 3 years through demonstrating business case for further sales to current HCP users, in targeting new HCPs, and realigning sales territories based on sales team workload/available capacity• Facilitated and led 25+ physician/stakeholder interviews by crafting an objective-driven discussion guide and analyzing interviewees' responses aimed in defining the strategy to increase sales of a medical device for the treatment of glaucoma

Performed competitor analysis and assessed potential market penetration prospects to enhance BioBeat's footprint within the burgeoning remote patient monitoring sector

Consolidated financial records collected from Sanofi’s $1.9B acquisition of Chattem Brands and analyzed data for budget and forecasting which enabled management to examine spending trends at a micro-level

Carried out market research on healthcare delivery systems for Autism Spectrum Disorder and formulated a financial model in accordance with a potential new drug opportunity to enable management's decision regarding the acquisition of the therapeutic